Figure 5

MM patient 3 predictive vs. experimental results. Predictive (A) vs. experimental (B) results regarding the effect of bortezomib and BEZ235 alone and in combination on cell proliferation in MM patient 3. Increasing doses of bortezomib are plotted on the x-axis, represented as fractions of concentration C (~70% target inhibition) for the predictive plot (A) and as micromolar concentrations of the drug in the experimental plot (B). The % change in proliferation from untreated baseline is plotted on the y-axis. Predictive results for the effect of bortezomib and BEZ235 alone and in combination on NFkβ (C) and cleaved-PARP1 (D), with the % change in the biomarker from untreated baseline plotted on the y-axis. (E) Western blot of non-treated (NT), bortezomib (BTZ) alone, BEZ235 (BEZ) alone and the combination (BTZ/BEZ) on the biomarkers NFkβ and cleaved PARP1. Actin serves as the loading control.